Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Date publication

janvier 2018

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine

Tous les auteurs :
Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29107348

Résumé

Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).

Mots clés

Adult, Aged, C-Reactive Protein, metabolism, Cohort Studies, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, blood, Ovarian Neoplasms, blood, Prognosis, Prospective Studies, ROC Curve, Reproducibility of Results, Serum Albumin, metabolism, Severity of Illness Index

Référence

Gynecol. Oncol.. 2018 01;148(1):36-41